← back to search

Jeffrey Girshman

Memorial Sloan Kettering Cancer Center · US
Area of research
Pulmonary and Respiratory Medicine · Cancer Research
Research interest
Research interests include Lung Cancer Treatments and Mutations, Lung Cancer Diagnosis and Treatment, Cancer Genomics and Diagnostics, and Lung Cancer Research Studies.
h-index
17
citations
2,162
works
107
NIH funding
primary concept
email

Recent publications

Body mass index and adiposity influence responses to immune checkpoint inhibition in endometrial cancer
Journal of Clinical Investigation 2024cited by 16position: middledoi
The GENIE BPC NSCLC Cohort: A Real-World Repository Integrating Standardized Clinical and Genomic Data for 1,846 Patients with Non–Small Cell Lung Cancer
Clinical Cancer Research 2023cited by 36position: middledoi
Chemotherapy response in low‐grade serous ovarian carcinoma at a comprehensive cancer center: Readdressing the roles of platinum and cytotoxic therapies
Cancer 2023cited by 18position: middledoi
Response to Repotrectinib After Development of <i>NTRK</i> Resistance Mutations on First- and Second-Generation TRK Inhibitors
JCO Precision Oncology 2023cited by 12position: middledoi
Predicting immunotherapy outcomes under therapy in patients with advanced NSCLC using dNLR and its early dynamics
European Journal of Cancer 2021cited by 60position: middledoi
<i>MET</i> Exon 14–altered Lung Cancers and MET Inhibitor Resistance
Clinical Cancer Research 2020cited by 78position: middledoi
Deep Learning to Estimate RECIST in Patients with NSCLC Treated with PD-1 Blockade
Cancer Discovery 2020cited by 67position: middledoi
Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib
Annals of Oncology 2019cited by 407position: middledoi
Harmonization of Tumor Mutational Burden Quantification and Association With Response to Immune Checkpoint Blockade in Non–Small-Cell Lung Cancer
JCO Precision Oncology 2019cited by 120position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Mark G. Kris · Kettering University4 papers (2019–2023)Hira Rizvi · AstraZeneca (United States)3 papers (2019–2020)Matthew D. Hellmann · Weill Cornell Medicine3 papers (2019–2020)Kathryn C. Arbour · University College London2 papers (2019–2020)Carol Aghajanian · AstraZeneca (Italy)2 papers (2023–2024)Gregory J. Riely · Weill Cornell Medicine2 papers (2019–2020)Alexander Drilon · Université Grenoble Alpes2 papers (2020–2023)Ahmet Zehir · Natera (United States)2 papers (2019–2020)Andrew J. Plodkowski · Manhattan Scientifics (United States)2 papers (2020–2024)Emiliano Cocco · University of Miami1 papers (2023–2023)Bob T. Li · Presbyterian Hospital1 papers (2020–2020)Kerry Scott · Johns Hopkins University1 papers (2020–2020)Todd Hembrough · Durham VA Medical Center1 papers (2020–2020)Paul Cohen · Rockefeller University1 papers (2024–2024)Lukas Delasos · University of Connecticut1 papers (2020–2020)S. Dennis · Twitter (United States)1 papers (2023–2023)Pasi A. Jänne · Harvard University1 papers (2019–2019)Andrew Pagano · Neurological Surgery1 papers (2024–2024)Charles M. Rudin · New York Proton Center1 papers (2020–2020)Anh Tuan Luu · Massachusetts Institute of Technology1 papers (2020–2020)